质量标准：【产品介绍】The principal human estrogen, 17 beta-
estradiol, is a potent stimulator of certain
endocrine-dependent forms of breast cancer. Because
human estrogenic 17 beta-hydroxysteroid
dehydrogenase (HSD17B1) catalyzes the last step in
the biosynthesis of 17 beta-estradiol from the less
potent estrogen, estrone, it is an attractive target for
the design of inhibitors of estrogen production and
tumor growth (1). It is concluded that the
steroid-binding site of human placental HSD17B1 contains
a histidine residue which proximates the upper A-ring
region of the steroid as it undergoes the reversible
binding step (2). Human estrogenic HSD17B1 is
an NADP(H)-preferring enzyme. It possesses 11- and
4-fold higher specificity toward NADP(H) over NAD(H)
for oxidation and reduction, respectively, as
demonstrated by kinetic studies (3). Defects in
the conversion of androstenedione to testosterone in
the fetal testes by the enzyme HSD17B1 give rise to
genetic males with female external genitalia (4)
Recommended Applications
WB, IHC, ICC, FC
Applications and Recommended Dilution Factors
WB: 1:500
IHC: 1: 100 - 250
ICC: 1:50
FC: 1:40
Species Reactivity *
Human
*Cross reactivity determined by western blot only.
Products Data
A. Western blot analysis on human placenta lysate
using anti-HSD17B1 RabMAb (cat. # 2127-1), dilution 1:500.
Immunohistochemical analysis of paraffin-embedded
human placenta tissue using anti-HSD17B1 RabMAb
(cat.# 2127-1).
Specificity
A synthetic peptide corresponding to residues on
the C-terminus of human HSD17B1 was used as an immunogen.
沪公网安备 31012002003055号